Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Today’s News

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Nov 12, 2024 5:04pm

111 Views

Post# 36309024

RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News

Your powers of reason and deduction are 2nd to none Buckster. What algorithm do you use to work out that a biotech needs cash before their product hits the market?

Can I interest you in a hobby? Maybe a friend? So that you can spend some time not on here being a silly Billy.

That share price going up today must have been a dagger in to that lonely heart of yours.

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3